New cocktail shows promise against tough rectal tumors
NCT ID NCT06024356
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at whether adding an immune-boosting drug called thymalfasin to standard chemoradiotherapy and a PD-1 inhibitor could help shrink advanced rectal tumors before surgery. Researchers studied 47 patients with stage II/III mid-low rectal cancer. The main goals were to see how many patients had no cancer left in the surgical specimen and how long they lived without the cancer coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
thymalfasin (thymosin-alpha 1) combined with chemoradiotherapy and a PD-1 inhibitor
What this could lead to
If this combination works better than standard treatment, it could point toward a more effective way to shrink rectal tumors before surgery and improve long-term survival.
What could go wrong
This is a small, single-center, retrospective study, not a large randomized trial. The results may not apply to all patients, and adding more drugs can increase side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friendship Hospital, Capital medical University
Beijing, Xicheng Dis, 100050, China